| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study
|
Bar, Jair
|
|
|
120 |
C |
p. 122-131
|
artikel
|
| 2 |
Can radiomics help to predict skeletal muscle response to chemotherapy in stage IV non-small cell lung cancer?
|
de Jong, E.E.C.
|
|
|
120 |
C |
p. 107-113
|
artikel
|
| 3 |
Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies
|
Corbaux, Pauline
|
|
|
120 |
C |
p. 40-46
|
artikel
|
| 4 |
Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation
|
Yuan, Ping
|
|
|
120 |
C |
p. 10-19
|
artikel
|
| 5 |
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion
|
Lluch, Ana
|
|
|
120 |
C |
p. 54-64
|
artikel
|
| 6 |
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
|
Kim, Hong Sook
|
|
|
120 |
C |
p. 65-74
|
artikel
|
| 7 |
Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia—a report from the UKALL 2011 trial
|
Jackson, Rosanna K.
|
|
|
120 |
C |
p. 75-85
|
artikel
|
| 8 |
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
|
Robson, Mark
|
|
|
120 |
C |
p. 20-30
|
artikel
|
| 9 |
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
|
Jones, Robin L.
|
|
|
120 |
C |
p. 132-139
|
artikel
|
| 10 |
Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer
|
Truntzer, Caroline
|
|
|
120 |
C |
p. 97-106
|
artikel
|
| 11 |
Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study
|
Hohenberger, Peter
|
|
|
120 |
C |
p. 47-53
|
artikel
|
| 12 |
Superior skin cancer classification by the combination of human and artificial intelligence
|
Hekler, Achim
|
|
|
120 |
C |
p. 114-121
|
artikel
|
| 13 |
The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy
|
Lee, Siow Ming
|
|
|
120 |
C |
p. 86-96
|
artikel
|
| 14 |
Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker
|
Chae, Heejung
|
|
|
120 |
C |
p. 31-39
|
artikel
|
| 15 |
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer
|
Pivot, Xavier
|
|
|
120 |
C |
p. 1-9
|
artikel
|
Tijdschrift beschrijving